Although the input of multiparameter flow cytometry (MFC) into the clinical management of multiple myeloma patients has faced some reluctance, continuously growing evidence supports the utility of MFC in this disease.
INTRODUCTION
Multiple myeloma is a plasma cell dyscrasia that accounts for 1% of all cancers and approximately 10% of all hematologic malignancies [1] . Almost all patients with multiple myeloma evolve from an asymptomatic premalignant stage termed monoclonal gammopathy of undetermined significance (MGUS) [2] . In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically, which progresses to multiple myeloma at a rate of approximately 10%/year over the first 5 years following diagnosis [3] .
Multiparameter flow cytometry (MFC) immunophenotyping is considered to be mandatory for the diagnosis and monitoring in a vast number of hematological malignancies [4] . Although multiple myeloma should be no exception, the input of MFC into the clinical management of these patients has faced some reluctance [5] . According to the International Myeloma Working Group (IMWG), clonality of plasma cells should be preferably established by immunohistochemistry because MFC immunophenotyping may still not be widely available and standardized for general use [6] . Furthermore, MFC affords lower bone marrow plasma cell frequencies vs. reference morphological approaches, which are partly explained by the association of plasma cell with lipid-enriched bone marrow spicules [7] . That notwithstanding, MFC is particularly well suited to study biological samples containing plasma cells because it allows: first, simultaneous identification and characterization of single plasma cells based on multiple parameters; second, evaluation of high cell numbers in a few hours; third, quantitative assessment of different cell populations and their corresponding antigen expression levels; and fourth, combined detection of cell surface and intracellular antigens [8 & ]. Accordingly, the utility of MFC in the management of multiple myeloma patients is here reviewed.
IMMUNOPHENOTYPIC DISCRIMINATION BETWEEN NORMAL VS. CLONAL BONE MARROW PLASMA CELLS AND CLINICAL OUTCOMES
There is strong evidence that the phenotypic characteristics of clonal plasma cells differ from their normal counterparts in terms of antigenic expression [4, 5] , and phenotypically aberrant plasma cells typically show among others: first, underexpression of CD19, CD27, CD38, and/or CD45; second, overexpression of CD28, CD33, and CD56 and/or third, asynchronous expression of CD20, CD117, and/or surface immunoglobulins. From a clinical point of view, the distinction between normal and clonal plasma cells has shown to be of clinical utility in first, the differential diagnosis between MGUS and multiple myeloma [9] ; second, the evaluation of the risk of transformation of MGUS and SMM into symptomatic multiple myeloma [10] ; and third, the identification of a subgroup of symptomatic multiple myeloma patients with favorable prognosis [11] . Accordingly, the Spanish Myeloma Group (GEM/PETHEMA) has made an effort to strengthen MFC immunophenotyping using novel EuroFlowbased software analysis tools to develop an automated classification model focused on the analysis of the plasma cell compartment, and capable of identifying newly diagnosed symptomatic multiple myeloma patients with a baseline MGUS-like profile (i.e., coexistence of normal and clonal plasma cells). This small subset (8% of all cases) shows unprecedented time to progression (TTP) rates of 59% at 10 years, and its prognosis is not dependent on the depth of response achieved [i.e., complete remission (CR) vs. no CR] [12] . The prospective identification of this signature may contribute to discriminate a suboptimal response that requires additional treatment from a residual 'MGUS-like component' that may remain stable without further treatment. In addition, the model also contributed to the identification of SMM patients at high risk of transformation to multiple myeloma (median TTP of 15 months) [12] . Noteworthy, the reference data set and classification algorithm developed can be equally built or shared across different myeloma centers; this is particularly relevant because of the perception that MFC immunophenotyping is difficult to standardize, and such technological developments that could help in standardizing MFC are mostly welcomed [13] .
QUANTIFICATION OF CIRCULATING TUMOR CELLS
The quantification of circulating tumor cells (CTCs) and its negative prognostic impact in plasma cell disorders has been demonstrated along the entire spectrum of the disease: from MGUS to SMM to newly diagnosed and relapsed/refractory multiple myeloma [14-17,18 & ]. In particular, high levels of CTCs identify SMM patients with high risk of progression within the first years following diagnosis (71% at 2 years) [14,18 & ], as well as symptomatic multiple myeloma patients with standard-risk cytogenetics but dismal overall survival (OS) because of high CTC numbers [15] . From a biologic point of view, we have recently shown that CTCs represent a unique subset from total bone marrow clonal plasma cells, with clonogenic potential and a quiescent phenotype, which may potentially be driven to circulate by circadian rhythms [19] . Thus, understanding the biologic features of CTCs may represent a unique model to understand and hopefully revert the extramedullary dissemination of multiple myeloma [20] .
MINIMAL RESIDUAL DISEASE MONITORING
At present, it is clear that in multiple myeloma there is a direct correlation between depth of response,
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MFC immunophenotyping of bone marrow and peripheral blood plasma cells affords cost-effective assessment of clonality, and provides prognostic information in MGUS and multiple myeloma.
MFC is one of the methods of choice for cost-effective yet highly sensitive, standardized MRD monitoring.
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particularly CR, and prolonged progression-free survival (PFS) as well as OS [21] . With the introduction of highly effective multidrug combinations almost 100% of overall response rates are observed, with over 50-80% of patients reaching CR. Because a significant proportion of patients relapse despite achieving these 'deep remissions', it becomes clear that the definition of CR would benefit from an improvement that matches the unprecedented evolution observed in the multiple myeloma treatment. Such improvement can only be accomplished by incorporating highly sensitive techniques able to detect minimal residual disease (MRD) at very low levels.
Several groups have demonstrated the utility of MFC in the detection of MRD [22] . In transplanteligible multiple myeloma patients, it has been shown that PFS of MRD-negative cases at least doubled that of MRD-positive CR patients [23] [24] [25] [26] [27] [28] [29] . Conversely, CR patients with persistent MRD had significantly inferior OS vs. MRD-negative cases. These results support the rationale for implementing MRD assessment to redefine and improve current CR criteria in multiple myeloma. Because an optimal balance between treatment efficacy and toxicity is of utmost importance in elderly multiple myeloma, sensitive MRD monitoring might be particularly valuable in this patient population. The prognostic value of MRD assessment, however, was not investigated outside of the stem cell transplantation (SCT) setting until recently, after the incorporation of novel agents into the treatment of patients who were not fit for SCT [24,30,31,32 & ,33] and subsequent increment in CR rates and prolonged survival. Most recently, we have used second-generation MFC to monitor MRD in 162 transplant-ineligible multiple myeloma patients enrolled in the PETHEMA/GEM2010MAS65 study. The transition from first to second generation MFC resulted in increased sensitivity, and patients' MRD status was an independent prognostic factor for TTP and OS [32 & ]. Accordingly (and similarly to transplant candidates), MRD monitoring is one of the most relevant prognostic factors in elderly multiple myeloma, irrespectively of patients' age and cytogenetic risk. This is particularly relevant because in multiple myeloma it has been suggested that attaining CR could be critical only for patients with high-risk disease, whereas those with more indolent biology may not particularly benefit. After the PETHEMA/GEM originally reported, however, that risk assessment by FISH and flow-MRD monitoring were of independent prognostic value [28] , Rawstron et al. [24] have reproduced and confirmed that the presence of MRD is a strong predictor of outcome in patients with both favorable and adverse cytogenetic profiles. Further analyses by the PETHEMA/GEM have shown that combined cytogenetic evaluation of plasma cells at diagnosis plus MRD assessment after SCT resulted in a highly effective approach to identify patients with unsustained CR and dismal outcomes (2 years median OS for cases with baseline high-risk cytogenetics plus persistent MRD) [27] .
As noted above, the sensitivity of MFC has recently increased because of simultaneous assessment of more than eight markers and evaluation of greater numbers of cells than what was previously feasible with analogical (4-color) instruments [32 & ]. Thus, the availability of more than 8-color digital flow cytometers coupled to novel sample preparation procedures that allow fast and cost-effective routine evaluation of more than 5 million nucleated cells has boosted the sensitivity of modern MFCbased MRD monitoring into that achieved on molecular grounds ( 10 À5 ). It should be noted that current sensitivity of MFC is at least 1 À log superior than that of previous MFC analyses (10 À4 ); therefore, ongoing MFC-based MRD monitoring should result in improved patient risk stratification vs. 4-or 6-color analyses. Equally important, 8-color flow-MRD methods incorporate a sample quality check of bone marrow cellularity via simultaneous detection of B-cell precursors, erythroblasts, myeloid precursors, and/or mast cells. This information is critical to ensure sample quality and to identify hemodiluted bone marrow aspirates that may lead to false-negative results [8 & ]. The need for extensive expertise to analyze flow cytometric data, together with the lack of well-standardized flow-MRD methods, have been pointed out as additional and perhaps the main limitations of conventional MFC immunophenotyping [8 & ]. However, new software programs have been developed in recent years with improved multidimensional identification and classification of different cell clusters coexisting in a sample (e.g., through principal component analysis and canonical analysis). These tools, together with the use of normal and tumor reference databases, allow for automated detection of normal vs. aberrant phenotypic profiles [4] . If such methods become now widely adopted, MFC would represent a method of choice for cost-effective yet highly sensitive, standardized MRD monitoring. Accordingly, the IMWG has most recently reported novel response criteria that include MRD monitoring and, amongst others, the flow-MRD-negative criterion: absence of phenotypically aberrant clonal plasma cells by nextgeneration flow cytometry on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum ] who have shown that the vast majority of CR patients achieving long-term survival (10 years relapse-free) were also MRD negative. However, attaining deep remission is not a prerequisite in order to achieve long-term disease control, at least in specific cases, and more accurate identification of such patients should also become a research priority. Accordingly, we have recently evaluated whether the bone marrow immune profile of individual patients at the time of MRD assessment could also be predictive of outcome, and developed individual patient immune signatures based on the unsupervised bone marrow distribution of 13 immune cell populations identified with the second-generation MFC assay. This approach revealed the existence of three patient clusters that were segregated by progressively increasing numbers of erythroblasts and B-cell precursors, together with progressively decreasing numbers of mature naïve and memory B-cells, and were associated with significantly different OS [32 & ]. These data showed for the first time that immune profiling in multiple myeloma after therapy, performed during MRD monitoring, may contribute to identify a subset of patients that albeit being MRD positive can still experience prolonged survival because of a unique immune signature specifically characterized by a more prominent regeneration of mature B-lymphocytes. In fact, a similar immune signature was previously found in both MRD-negative and MRDpositive multiple myeloma patients reaching longterm disease control [36] .
From a biologic point of view, it should be noted that MRD represents a very small fraction of all diagnostic tumor cells which are chemoresistant, potentially quiescent (not producing M-protein), and able to recapitulate the initial tumor burden at relapse. Thereby, a better understanding of the biologic signature of MRD vs. diagnostic cells could potentially contribute to gain insight in the mechanisms of chemoresistance at the MRD level, and the potential discovery of novel therapeutic targets. In this regard, we have recently reported for the first time the biologic features of MRD cells in multiple myeloma [37 && ,38]. Overall, our results revealed that the MRD subclone is enriched in cells overexpressing integrins (CD11a/CD11c/CD29/CD49d/ CD49e), chemokine receptors (CXCR4), and adhesion molecules (CD44/CD54). Genetic profiling of MRD vs. diagnostic plasma cells showed either identical copy number alterations (CNAs) or additional CNAs that emerged at the MRD stage. Accordingly, the MRD subclone showed significant downregulation of genes related to protein processing in endoplasmic reticulum, as well as novel deregulated genes such as ALCAM that is prognostically relevant in multiple myeloma and may identify chemoresistant plasma cells in vitro. Altogether, these results suggested that therapyinduced clonal selection could be already present at the MRD stage, whereas chemoresistant plasma cells show a singular phenotypic signature that may result from the persistence of clones with different genetic and gene expression profiles [37 && ].
OTHER CLINICAL APPLICATIONS OF MULTIPARAMETER FLOW CYTOMETRY IMMUNOPHENOTYPING
As noted above, MFC is commonly used to monitor MRD in multiple myeloma because of its widespread availability, fast turnaround, and the amount of information obtained upon enumeration of different cell populations and their corresponding antigen expression levels. Thus, MFC could potentially be used not only to monitor MRD, but also to offer additional prognostic information based on multiple myeloma plasma cell phenotypes. One of such markers is CD117, for which the favorable prognosis of CD117þ multiple myeloma patients [39] has been hypothesized because of an altered homing of clonal plasma cells in the bone marrow toward neutrophil precursor niches, thereby contributing to a greater maintenance of residual normal plasma cells [40] . Conversely, the adverse prognosis associated to CD28 expression initially attributed to a strong association with adverse cytogenetic alterations [39] , has been more recently related to a prosurvival signaling provided through plasma celldendritic cell interaction [41, 42] . CD19 expression has been described in 5-10% of multiple myeloma cases [39] , and conferred inferior survival in a series of transplant-eligible patients treated prior to the incorporation of novel agents [39] . More recent studies from our group showed that the expression of CD81 in clonal plasma cells is an independent prognostic factor for patients with symptomatic multiple myeloma and a marker for risk of progression in SMM [43] . In fact, we have most recently demonstrated in healthy individuals that the CD19ÀCD81 expression axis identifies three bone marrow plasma cell subsets with distinct age prevalence, proliferation, replication history, immunoglobulin production, and phenotype, consistent with progressively increased differentiation from CD19þCD81þ into CD19ÀCD81þ and CD19ÀCD81À bone marrow plasma cells [44] . Subsequently, we demonstrated that myeloma plasma cells fit into such a model of normal bone marrow plasma cell differentiation, and that patients with less-differentiated clones had dismal survival. Plasma cell differentiation is also related to therapyinduced selective pressure, through which lessdifferentiated plasma cell subclones become enriched from diagnosis into MRD stages in a subset of multiple myeloma patients. Most interestingly, less-differentiated plasma cells maintain the expression of genes related to preceding B-cell stages, and show different mutation profiles as compared to fully-differentiated plasma cell subclones within individual multiple myeloma patients [44] . These observations have shed new light into plasma cell plasticity and demonstrated that multiple myeloma patients harboring less-differentiated plasma cells have dismal survival, which might be related to higher chemoresistant potential plus different molecular and genomic profiles [44] . In the same way, the breakthrough of immunotherapy in multiple myeloma makes MFC an attractive technique to measure the expression of novel therapeutic targets such as CD38, SLAMF7, or the PD-1/PD-L1 axis [45] .
The assessment of plasma cell ploidy and proliferation has been long shown to provide prognostic information in multiple myeloma. It should be noted, however, that while the detection of both nonhyperdiploid DNA content highly proliferative plasma cells are of independent prognostic value for OS in newly diagnosed multiple myeloma patients, treatment with bortezomib-based regimens might abrogate the inferior OS of patients with 1% or more plasma cells in S-phase [46] . Thus, the prognostic value of MFC-based DNA studies should be revisited.
On a different note, multiple myeloma patients are living longer with increasingly effective therapies, but long-term complications including second primary malignancies (SPMs) are becoming new challenges in designing optimal patient care. It has been demonstrated in large studies that among others, risk is particularly high for SPMs such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [47] . Importantly, such increased risk of MDS/AML has also been observed in MGUS patients [48] , suggesting that increased risk for MDS/AML may not only be treatment related but inheritably high in MGUS/multiple myeloma. Thus, there is need to investigate for biomarkers that uncover cellular alterations predisposing for higher risk of MDS/AML in multiple myeloma. Recently, we have shown that in a small proportion of multiple myeloma and SMM patients, phenotypic alterations detected by high-sensitivity MFC immunophenotyping are already present in bone marrow hematopoietic cell compartments at diagnosis [49] . Moreover, our results showed that phenotypic alterations may uncover a genetically abnormal bone marrow hematopoiesis [50] , and did not support a protective nor a triggering effect between Len/Dex and MDS development [49] . Given the multiple therapeutic options currently available in multiple myeloma, the information provided by these biomarkers should be integrated in clinical trials, wherein the prospective identification of patients at higher risk of developing SPMs such as MDS/AML should become a goal [50] .
CONCLUSION
In the past, MFC immunophenotyping of plasma cells has not been routinely applied in many laboratories for the diagnosis and monitoring of patients with multiple myeloma. However, at present consensus exists about the clinical utility of MFC in at least three different areas (Table 1) : first, the differential diagnosis and classification of plasma cell disorders; second, prognostic stratification of MGUS, SMM, or multiple myeloma; and third, MRD monitoring. Thus, MFC immunophenotypic studies should be considered mandatory in the Table 1 . Utility of flow cytometry studies in the management of patients with multiple myeloma
Disease stage Application References
Smoldering multiple myeloma Prediction of risk of progression based on the ratio of normal vs. clonal plasma cells within the bone marrow plasma cell compartment [10, 12] Prediction of risk of progression based on the number of CTCs in peripheral blood [14,18 & ] Active multiple myeloma Identification of MGUS-like patients based on the persistence of normal plasma cells [12] Prognostic information based on the antigen profile of clonal plasma cells [39, 43, 44] Assessment of potential therapeutic targets [45] Detection of MDS-like phenotypic abnormalities in other hematopoietic cells [49, 50] MRD monitoring [23-25,27-29, 31,32 & ,33] CTCs, circulating tumor cells; MDS, myelodysplastic syndrome; MGUS, monoclonal gammopathy of undetermined significance; MRD, minimal residual disease.
Flow cytometry in management of multi ple myeloma patients Paiva et al. routine evaluation of multiple myeloma patients both at diagnosis and after therapy. In the same way, MFC has greatly contributed to a better understanding of multiple myeloma pathogenesis and chemoresistance.
